Abstract Number: 1025 • ACR Convergence 2022
Entheseal Biopsy Approach: An Ultrasound-guided Method for Retrieval of Entheseal Tissue from Psoriatic Arthritis Patients
Background/Purpose: Enthesitis as hallmark feature of psoriatic arthritis (PsA) has been mostly addressed through clinical assessment and imaging evaluation, such as MRI or musculoskeletal ultrasound.…Abstract Number: 1155 • ACR Convergence 2022
Epigenome-Wide Integrative Association Study on Spondyloarthritis and Psoriatic Arthritis
Background/Purpose: An important role of DNA methylation changes in Spondylitis Ankylosing has been recently demonstrated by epigenome-wide studies. However, there is a lack of genome-wide…Abstract Number: 1426 • ACR Convergence 2022
Year-two Follow-up Results of an Observational Study Conducted in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis Patients Treated with Infliximab Biosimilar CT-P13 in a Real-life Setting
Background/Purpose: ReFLECT study has been carried out to investigate real life use of CT-P13, the first monoclonal antibody biosimilar to infliximab (IFX) originator.Methods: ReFLECT is…Abstract Number: 1507 • ACR Convergence 2022
Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Outcome Measures in Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a type of inflammatory arthritis in which the time between symptom onset and a diagnosis of PsA is highly variable.…Abstract Number: 1769 • ACR Convergence 2022
Comparative Evaluation of Adverse Events Associated with Subcutaneous Infliximab (CT-P13 SC) and Intravenous Infliximab: A Real-world Analysis of Post-marketing Surveillance Data
Background/Purpose: The first subcutaneous (SC) formulation of infliximab (IFX) received approval for the treatment of rheumatoid arthritis (RA), Crohn's disease (CD), ulcerative colitis (UC), ankylosing…Abstract Number: 2121 • ACR Convergence 2022
Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are most often the first choice biologic treatment for patients with psoriatic arthritis (PsA). When their discontinuation is needed,…Abstract Number: 2138 • ACR Convergence 2022
Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy
Background/Purpose: Interleukin-17A inhibitors (anti-IL17) have provided an additional treatment option in the management of the psoriatic arthritis (PsA). This study aims to describe the patient…Abstract Number: 2201 • ACR Convergence 2022
Increased Economic Burden of Uveitis Among Patients with Psoriasis and Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2022
Background/Purpose: Uveitis occurs more frequently in patients (pts) with psoriatic disease than in the general population,1-2 yet little is known about the increased burden associated…Abstract Number: 0082 • ACR Convergence 2022
Impact of the COVID-19 Pandemic on Healthcare Utilization Among Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) are considered at risk for serious COVID infections due to their…Abstract Number: 0390 • ACR Convergence 2022
Persistent Post-Covid Symptoms in Psoriatic Arthritis Patients
Background/Purpose: Symptomatic onset long after recovery from the acute phase of COVID-19 infection has been reported by the population. Currently, it is not known how…Abstract Number: 0796 • ACR Convergence 2022
SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFI Impaired Immunogenicity?
Background/Purpose: Spondyloarthritis(SpA) patients are exposed to a variety of immunosuppressors capable of reduce humoral responses to vaccination. In context of the SARS-CoV-2 pandemic, assessment of…Abstract Number: 1026 • ACR Convergence 2022
Responsiveness and Minimal Clinically Important Difference in Patient-Reported Outcome Measures Among Patients with Psoriatic Arthritis
Background/Purpose: Despite significant heterogeneity in psoriatic arthritis (PsA), randomized controlled trials (RCTs) generally enroll a homogenous subgroup of PsA patients (polyarticular similar to rheumatoid arthritis).…Abstract Number: 1159 • ACR Convergence 2022
Uveitis in Psoriatic Arthritis: Study of 406 Patients in a Single University Center
Background/Purpose: The manifestations of uveitis are well-established in Axial Spondyloarthritis (ax-SpA), but not in Psoriatic Arthritis (PsA). We aimed to assess, in a large unselected…Abstract Number: 1433 • ACR Convergence 2022
A 48-week Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Background/Purpose: SB5, a biosimilar to reference adalimumab (ADL), received marketing authorisation in 2017 (EU) and 2019 (US) based on pre-clinical and clinical phase I and…Abstract Number: 1508 • ACR Convergence 2022
Enthesitis a Dominant Pathology in Psoriatic Arthritis: Identification and Quantification of Enthesitis Burden by 18F-FDG Total-Body PET/CT Imaging
Background/Purpose: The enthesitis can be the earliest/primary inflammatory event in psoriatic arthritis (PsA). Clinically most of the entheses are not accessible and can't be assessed;…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 60
- Next Page »